ES2163512T3 - Nuevo compuesto, procedimiento para producirlo, y agente antitumoral. - Google Patents

Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.

Info

Publication number
ES2163512T3
ES2163512T3 ES95920265T ES95920265T ES2163512T3 ES 2163512 T3 ES2163512 T3 ES 2163512T3 ES 95920265 T ES95920265 T ES 95920265T ES 95920265 T ES95920265 T ES 95920265T ES 2163512 T3 ES2163512 T3 ES 2163512T3
Authority
ES
Spain
Prior art keywords
group
hydrogen atom
sub
low
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95920265T
Other languages
English (en)
Spanish (es)
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2163512T3 publication Critical patent/ES2163512T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES95920265T 1994-06-14 1995-06-06 Nuevo compuesto, procedimiento para producirlo, y agente antitumoral. Expired - Lifetime ES2163512T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (fr) 1994-06-14 1995-06-06 Nouveau compose, son procede de production et agent antitumoral

Publications (1)

Publication Number Publication Date
ES2163512T3 true ES2163512T3 (es) 2002-02-01

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95920265T Expired - Lifetime ES2163512T3 (es) 1994-06-14 1995-06-06 Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.

Country Status (26)

Country Link
US (1) US5817669A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0787726B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3391796B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100350921B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1053668C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE209645T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679859B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9508037A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2192824C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ292631B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69524251T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0787726T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2163512T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI112485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU220072B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9606331A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO307255B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ287139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL181867B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT787726E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117793B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2151770C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0787726T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK281341B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW319769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995034559A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL369531A1 (en) * 2001-09-26 2005-05-02 Bayer Pharmaceuticals Corporation 1,8-naphthyridine derivatives as antidiabetics
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
ES2424676T3 (es) * 2003-09-10 2013-10-07 Kyorin Pharmaceutical Co., Ltd. Derivado de ácido 7-(3-ciclopropilaminometil-1-pirrolidinil 4-sustituido)quinoloncarboxílico
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
CA2954578A1 (en) * 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
RU2405781C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг 1, 5-нафтиридиназолидиноны, обладающие cdk1 антипролиферативной активностью
CA2583311A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Quinazolinylmethylenethiazolinones as cdk1 inhibitors
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームDNA(rDNA)およびリボソームRNA(rRNA)核酸ならびにそれらの使用
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
KR20170118936A (ko) * 2005-09-02 2017-10-25 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (+)-1,4-디히드로-7-[(3s,4s)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
BRPI0615838A2 (pt) * 2005-09-14 2011-05-31 Janssen Pharmaceutica Nv 5-oxo-5,8-dihidro-pirido-pirimidinas como inibidores de ofc-fms cinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
BRPI0713637A2 (pt) * 2006-06-12 2012-10-23 Sunesis Pharmaceuticals Inc composição, composto, e , método para o tratamento de cáncer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
MX344865B (es) * 2006-08-02 2016-12-19 Sunesis Pharmaceuticals Inc Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
CA2703044C (en) * 2007-10-22 2016-05-10 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
AU2008335772B2 (en) * 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
BRPI0923780A2 (pt) * 2008-12-31 2015-07-21 Sunesis Pharmaceuticals Inc Processo para preparar composto, processo para decomposição do composto, composto, composição, método para tratar câncer, e, pelo menos um quilograma de composto
SG173855A1 (en) 2009-02-27 2011-09-29 Sunesis Pharmaceuticals Inc Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2712358B1 (en) 2011-05-13 2016-12-21 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
WO2018174266A1 (ja) 2017-03-24 2018-09-27 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
GR861530B (en) * 1985-06-13 1986-12-31 Schering Corp Preparation process for polycyclic quinoline of naphthyridine and pyrazinopyridine
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
HU220072B (hu) 2001-10-28
WO1995034559A1 (fr) 1995-12-21
KR100350921B1 (ko) 2002-11-18
FI965020A7 (fi) 1996-12-16
AU679859B2 (en) 1997-07-10
EP0787726B1 (en) 2001-11-28
PT787726E (pt) 2002-04-29
SI0787726T1 (en) 2002-04-30
BR9508037A (pt) 1997-09-16
JP3391796B2 (ja) 2003-03-31
EP0787726A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-08-06
NO965305L (no) 1997-02-04
MX9606331A (es) 1997-03-29
DK0787726T3 (da) 2002-02-11
AU2576795A (en) 1996-01-05
EP0787726A1 (en) 1997-08-06
DE69524251D1 (de) 2002-01-10
HK1000495A1 (en) 2002-07-19
HU9603455D0 (en) 1997-02-28
NZ287139A (en) 1997-07-27
NO965305D0 (no) 1996-12-11
RU2151770C1 (ru) 2000-06-27
FI965020A0 (fi) 1996-12-13
CA2192824A1 (en) 1995-12-21
DE69524251T2 (de) 2002-07-11
CZ292631B6 (cs) 2003-11-12
CN1158614A (zh) 1997-09-03
RO117793B1 (ro) 2002-07-30
HUT75777A (en) 1997-05-28
PL317726A1 (en) 1997-04-28
SK157496A3 (en) 1997-08-06
CN1053668C (zh) 2000-06-21
CA2192824C (en) 2006-11-07
FI112485B (fi) 2003-12-15
SK281341B6 (sk) 2001-02-12
ATE209645T1 (de) 2001-12-15
CZ364396A3 (en) 1997-06-11
TW319769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-11-11
PL181867B1 (pl) 2001-09-28
NO307255B1 (no) 2000-03-06
US5817669A (en) 1998-10-06

Similar Documents

Publication Publication Date Title
ES2163512T3 (es) Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.
DE69513383D1 (de) Substituierte 3-arylidinene-7-azaoxindol verbindungen und verfahren zu ihrer herstellung
ES2124612T3 (es) Dihidrodibenzo(b,f)azepinas, substituidas, metodo para su preparacion, su utilizacion en el tratamiento de diversos trastornos del sistema nervioso central y composiciones farmaceuticas que las contienen.
AR002260A1 (es) Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
ES543786A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dietilaminoalcoxi sustituido y sus sales deadicion acidas y amonicas cuaternarias
ES2039485T3 (es) Un procedimiento para la preparacion de un compuesto 3,4-dihidropirimidina n-sustituido.
ES543802A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo n-carbamiloxi sustituido
ATE52776T1 (de) 1-phenyl-3-benzazepine.
ES2183476T3 (es) Procedimiento de preparacion del acido 3-isoxazol-carboxilico.
ES555464A0 (es) Procedimiento para preparar dihidro-1,4-tiazinas aroil-sustituidas
PH15932A (en) Method for treating inflammation
ES543790A0 (es) Procedimiento de preparacion de nuevos derivados a-etilami- noetoxibencilalcoholicos con un grupo fenil sustituido en situacion a y de sus sales de adicion acidas y amonicas cua-ternarias
SE8404720L (sv) Forfarande for framstellning av kondenserade as-triazinderivat
ES493044A0 (es) Un procedimiento para la preparacion de agentes antibacterianos beta-lactanicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 787726

Country of ref document: ES